# US 2015/0177246 A1 · Fusion gene of cep55 gene and ret gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177246 A1
- Document ID: US20150177246A1
- Status: Published application
- Kind: A1
- Application number: 14/417,052
- Filed: 2013-07-23
- Published: 2015-06-25
- Earliest claimed: 2012-07-26
- Assignees: Lsip, LLC; National Caner Center
- Applicants: National Cancer Center; Lsip, LLC
- Inventors: Tatsuhiro Shibata; Fumie Hosoda
- Web page: https://patentgrep.com/patent/US20150177246A1

## CPC

- G01N 33/57575: {involving oncogenic proteins}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/82: Translation products from oncogenes
- C07K 16/32: against translation products of oncogenes
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1)
- G01N 33/575: for cancer
- G01N 33/5753: of the stomach or small intestine
- C07K 2319/00: Fusion polypeptide
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of diffuse-type gastric cancer. As a result, in-frame fusion transcripts between the CEP55 gene and the RET gene were identified. It was also found that said gene fusions induce activation of RET protein, thereby causing canceration of cells. Further, it was demonstrated that the RET protein activation and canceration caused by said gene fusion can be suppressed by using a RET tyrosine kinase inhibitor, and that treatments with a RET tyrosine kinase inhibitor are effective in patients with detection of said gene fusion.

## Claims

### Claim 1

A polynucleotide encoding a polypeptide in which CEP55 protein or part thereof and RET protein or part thereof are fused together.

### Claim 2 (depends on 1)

A polypeptide encoded by the polynucleotide according to claim 1.

### Claim 3 (depends on 1)

A method for detecting the presence or absence in a sample of the polynucleotide according to claim 1, the method comprising the steps of:
(a) contacting the sample with an agent intended for specifically detecting the presence or absence of the polynucleotide in the sample; and
(b) detecting the presence or absence of the polynucleotide.

### Claim 4 (depends on 3)

An agent for detecting the presence or absence in a sample of a polynucleotide encoding a polypeptide in which CEP55 protein or part thereof and RET protein or part thereof are fused together for use in the method according to claim 3, the agent comprising a polynucleotide or polynucleotides as set forth below in any one of (a) to (c), the polynucleotide or polynucleotides having a chain length of at least 15 nucleotides:
(a) a polynucleotide or polynucleotides that are at least one probe selected from the group consisting of a probe that hybridizes to a polynucleotide encoding CEP55 protein and a probe that hybridizes to a polynucleotide encoding RET protein;
(b) a polynucleotide that is a probe that hybridizes to a point of fusion between a polynucleotide encoding CEP55 protein and a polynucleotide encoding RET protein; and
(c) polynucleotides that are a pair of primers designed to sandwich a point of fusion between a polynucleotide encoding CEP55 protein and a polynucleotide encoding RET protein.

### Claim 5 (depends on 1)

A method for determining the effectiveness of a cancer treatment with a RET tyrosine kinase inhibitor, the method comprising the step of detecting the presence or absence in a sample isolated from a patient of the polynucleotide according to claim 1, wherein in a case where the presence of the polynucleotide is detected, the cancer treatment with the RET inhibitor is determined to be highly effective in the patient.

### Claim 6 (depends on 5)

An agent for determining the effectiveness of a cancer treatment with a RET inhibitor by the method according to claim 5, the agent comprising a polynucleotide or polynucleotides as set forth below in any one of (a) to (c), the polynucleotide or polynucleotides having a chain length of at least 15 nucleotides:
(a) a polynucleotide or polynucleotides that are at least one probe selected from the group consisting of a probe that hybridizes to a polynucleotide encoding CEP55 protein and a probe that hybridizes to a polynucleotide encoding RET protein;
(b) a polynucleotide that is a probe that hybridizes to a point of fusion between a polynucleotide encoding CEP55 protein and a polynucleotide encoding RET protein; and
(c) polynucleotides that are a pair of primers designed to sandwich a point of fusion between a polynucleotide encoding CEP55 protein and a polynucleotide encoding RET protein.

### Claim 7 (depends on 5)

A method for treatment of cancer, comprising the step of administering a RET tyrosine kinase inhibitor to a patient in whom a cancer treatment with the RET tyrosine kinase inhibitor has been determined to be highly effective by the method according to claim 5.

### Claim 8 (depends on 5)

A therapeutic agent for cancer, comprising a RET tyrosine kinase inhibitor as an active ingredient, wherein the therapeutic agent is to be administered to a patient in whom a cancer treatment with the RET tyrosine kinase inhibitor has been determined to be highly effective by the method according to claim 5.

### Claim 9 (depends on 2)

A method for detecting the presence or absence in a sample of the polypeptide according to claim 2, the method comprising the steps of:
(a) contacting the sample with an agent intended for specifically detecting the presence or absence of the polypeptide in the sample; and
(b) detecting the presence or absence of the polypeptide.

### Claim 10 (depends on 9)

An agent for detecting the presence or absence in a sample of a polypeptide in which CEP55 protein or part thereof and RET protein or part thereof are fused together for use in the method according to claim 9, the agent comprising an antibody as set forth below in (d):
(d) an antibody that binds to a polypeptide in which CEP55 protein and RET protein are fused together.

### Claim 11 (depends on 2)

A method for determining the effectiveness of a cancer treatment with a RET tyrosine kinase inhibitor, the method comprising the step of detecting the presence or absence in a sample isolated from a patient of the polypeptide according to claim 2, wherein in a case where the presence of the polypeptide is detected, the cancer treatment with the RET inhibitor is determined to be highly effective in the patient.

### Claim 12 (depends on 11)

An agent for determining the effectiveness of a cancer treatment with a RET inhibitor by the method according to claim 11, the agent comprising an antibody as set forth below in (d):
(d) an antibody that binds to a polypeptide in which CEP55 protein and RET protein are fused together.

### Claim 13 (depends on 11)

A method for treatment of cancer, comprising the step of administering a RET tyrosine kinase inhibitor to a patient in whom a cancer treatment with the RET tyrosine kinase inhibitor has been determined to be highly effective by the method according to claim 11.

### Claim 14 (depends on 11)

A therapeutic agent for cancer, comprising a RET tyrosine kinase inhibitor as an active ingredient, wherein the therapeutic agent is to be administered to a patient in whom a cancer treatment with the RET tyrosine kinase inhibitor has been determined to be highly effective by the method according to claim 11.
